Latest Biotech News

Innovent Biologics disclosed that its Claudin18.2 antibody-drug conjugate arcotatug tavatecan (IBI-343, TAK-921) met a primary endpoint in an international Phase 3 study (G-Hope-001) for advanced...

Finerenone’s clinical footprint expanded after the Phase III FIND-CKD trial reported benefits in non-diabetic chronic kidney disease. Investigators found that the non-steroidal mineralocorticoid...

Innovent, fresh from a major licensing arrangement with Takeda, reported a Phase 3 win for its Claudin18.2-directed ADC arcotatug tavatecan (IBI-343, TAK-921) in advanced gastric cancer. The...

Ona Therapeutics closed an oversubscribed Series B financing totaling $86.6 million to advance two antibody-drug conjugates targeting treatment-resistant cancers. The money primarily supports...

Zepto Life Technology received FDA breakthrough device designation for its FungiFlex Mold Panel, a plasma-based assay designed to detect invasive mold infections via circulating cell-free DNA. The...

Deep Science Ventures and Medicine Discovery Catapult launched a partnership aimed at overcoming one of the field’s central bottlenecks—delivering medicines across the blood-brain barrier. The...

Cellares and TScan Therapeutics agreed to evaluate automated manufacturing for TSC-101, TScan’s TCR-T therapy candidate intended for patients with AML and MDS undergoing allogeneic hematopoietic...

Fulcrum Therapeutics reduced its workforce, letting go 48 of 57 full-time employees following disclosures in an SEC filing. The company’s restructuring comes as it attempts to preserve runway...

Parabilis Medicines is preparing for a planned IPO seeking to raise more than $400 million to fund phase 3 development of its desmoid tumor drug prospect. The filing process is aimed at providing...

Servier moved to deepen its neurology strategy by acquiring Edgewise’s sevasemten and signaling continued M&A buildout across therapeutic franchises. The deal underscores how large pharma is using...

Alnylam agreed a multi-year, potentially $2 billion AI collaboration with Inceptive Nucleics to accelerate discovery of RNA interference therapies. The agreement includes $30 million upfront and...

A pair of kidney-focused developments pushed mineralocorticoid and drug-safety questions to the forefront. In the largest non-diabetic chronic kidney disease trial, Phase III FIND-CKD reported...

On the ADC front, Innovent’s CLDN18.2-targeted arcotatug tavatecan (IBI-343) cleared another milestone after interim Phase III results in G-Hope-001, with the company submitting an NDA to China’s...

Researchers at the MRC Laboratory of Molecular Biology in Cambridge identified how TRIM21 can drive antibody-directed xenophagy, detailing genes involved in an intracellular degradation pathway...

Abbott and Mayo Clinic validated a tampon-based endometrial cancer test that uses PCR detection of DNA methylation markers from self-collected vaginal fluid. The platform is designed as a less...

The FDA’s Commissioner’s National Priority Voucher program faced heightened scrutiny as patient groups, drug companies, and academic organizations urged the agency to pause and restart the voucher...

ADC Therapeutics’ Lotis-5 confirmatory study continued to reverberate after safety signals complicated the company’s path to full DLBCL approval. Data showed no overall survival benefit and a...

CereVasc raised $85 million to advance its minimally invasive eShunt system targeting hydrocephalus without traditional brain shunt surgery. The company said it is preparing to complete a pivotal...

Ona Therapeutics closed an oversubscribed $86.6 million Series B to push two antibody-drug conjugates into human testing, including ONA-255 for breast cancer and ONA-389 for colorectal cancer. The...

Travere Therapeutics moved to expand its rare-disease kidney pipeline, signing a global licensing deal with Everest Medicines for civorebrutinib, a covalent reversible BTK inhibitor. The...